Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Haemonetics (NYSE: HAE) announced that President and CEO Chris Simon will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 AM PT.

The presentation will be available live via audio webcast at the provided JPMorgan link and under the Events & Presentations section of Haemonetics' Investor Relations website. A replay will be posted approximately one hour after the live event and will remain available for 30 days.

Key Figures

JPM presentation time 7:30 am Pacific Time J.P. Morgan Healthcare Conference, January 13, 2026

Q2 2026 net revenues $327.3 million Three months ended September 27, 2025

Q2 2026 gross profit $194.7 million Three months ended September 27, 2025

Q2 2026 operating income $58.5 million Three months ended September 27, 2025

Q2 2026 diluted EPS $0.81 Quarter ended September 27, 2025

Operating cash flow $128.7 million Six months ended September 27, 2025

Impairment charge $8.6 million Hospital business intangibles

ASR repurchase $75.0 million (1,430,579 shares at $52.43) Accelerated share repurchase in August 2025

Market Reality Check

$82.11 Last Close

Volume Volume 336,907 is below 20-day average of 724,377, suggesting limited pre-conference positioning. low

Technical Shares at $80.15 are trading above the $65.04 200-day moving average, reflecting a pre-news uptrend.

Peers on Argus

While HAE slipped -1.02%, key peers like ATEC, INSP, ITGR and PRCT showed modest gains between 0.25% and 0.60%, with only LIVN down -1.27%, indicating a largely stock-specific move ahead of the conference.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 06	Q2 2026 results posted	Neutral	+32.3%	Q2 fiscal 2026 financials and materials posted with investor webcast replay.
Oct 09	Q2 2026 date set	Neutral	-2.6%	Announcement of Q2 fiscal 2026 release and conference call schedule.
Aug 07	Q1 2026 results posted	Neutral	-26.6%	Q1 fiscal 2026 results made available with accompanying webcast details.
Jul 09	Q1 2026 date set	Neutral	+0.8%	Scheduling announcement for Q1 fiscal 2026 release and investor call.

Pattern Detected

Earnings-related webcasts have produced volatile reactions, with both sharp rallies and selloffs following posting of results.

Recent Company History

Over the past six months, Haemonetics focused investor communication around fiscal 2026 earnings. It scheduled and then released first and second quarter results on August 7, 2025 and November 6, 2025, each paired with webcasts and year-long replays on the Investor Relations site. Price reactions ranged from a -26.58% drop to a 32.31% gain, underscoring sensitivity to earnings details. Today’s J.P. Morgan conference appearance extends this pattern of active investor outreach via webcasts.

Market Pulse Summary

This announcement highlights Haemonetics’ plan to present at the J.P. Morgan Healthcare Conference, extending its pattern of active webcasts and investor outreach. Recent filings showed Q2 net revenues of $327.3 million, rising gross profit of $194.7 million, and operating cash flow of $128.7 million, alongside an $8.6 million impairment and a $75.0 million share repurchase. Investors may watch how conference commentary reinforces these trends and past strategic moves.

Key Terms

audio webcast technical

"The public may access Mr. Simon's presentation live via audio webcast at:"

An audio webcast is a live or recorded audio broadcast transmitted over the internet, allowing listeners to hear presentations, discussions, or updates in real time or on demand. For investors, it provides a way to stay informed about company news, market trends, or industry insights without needing to attend in person, similar to listening to a radio program but accessible from any device.

investor relations financial

"Events & Presentations section of Haemonetics' Investor Relations website."

Investor relations is the communication process between a company and its current or potential investors. It involves sharing information about the company's performance, strategies, and outlook to help investors make informed decisions. Effective investor relations build trust and transparency, similar to a clear conversation between a business and someone considering investing, ensuring both parties understand each other's interests and expectations.

form 4 regulatory

"reported an insider share purchase on Form 4."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

10-q regulatory

"Haemonetics Corporation Quarterly Earnings Report"

A 10-Q is a company’s required quarterly filing with U.S. regulators that provides updated financial statements, management discussion of results, and disclosures about risks, legal matters and operational changes. Think of it as a quarterly report card and progress update that lets investors track recent performance, spot trends or warning signs between annual reports, and make informed buy/sell decisions based on the latest verified financial and business information.

8-k regulatory

"Haemonetics Corporation Reports Material Event"

An 8-K is a public report companies must file with the U.S. Securities and Exchange Commission to disclose major events or changes that shareholders should know about, such as leadership changes, mergers, financial surprises, or legal developments. It matters to investors because it acts like a breaking-news alert for a company’s health and prospects—providing timely facts that can affect stock value and investment decisions.

restricted stock units financial

"includes unvested restricted stock units that were previously reported."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

operating cash flow financial

"Operating cash flow strengthened to $128.7 million from $21.4 million,"

Operating cash flow is the amount of money a company earns from its main business activities, like selling products or services. It shows how well the company can generate cash to pay bills, invest in growth, or return money to shareholders. This figure helps investors understand if the company’s core operations are healthy and sustainable.

impairment financial

"The company recorded an $8.6 million impairment of certain Hospital business intangibles."

Impairment occurs when the value of an asset, such as property, equipment, or investments, drops below its recorded worth on the books. This situation signals that the asset may be less valuable than originally thought, similar to discovering that an item you own is worth less than what you paid for it. For investors, recognizing impairment is important because it can affect the overall financial health and future prospects of a business.

AI-generated analysis. Not financial advice.

BOSTON, Jan. 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 am Pacific Time.

The public may access Mr. Simon's presentation live via audio webcast at:

https://jpmorgan.metameetings.net/events/healthcare26/sessions/317152-haemonetics-corp/webcast?gpu_only=true&kiosk=true

The live webcast can also be accessed under the Events & Presentations section of Haemonetics' Investor Relations website. The replay of the presentation will be available for 30 days using the link provided above and on Haemonetics' Investor Relations website beginning approximately one hour after completion of the live event.

ABOUT HAEMONETICS

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:
Olga Guyette, Vice President-Investor Relations & Treasury	David Trenk, Manager-Investor Relations
(781) 356-9763	(203) 733-4987
olga.guyette@haemonetics.com	david.trenk@haemonetics.com
Media Contact:
Josh Gitelson, Sr. Director-Global Communications
(781) 356-9776
josh.gitelson@haemonetics.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-to-present-at-44th-annual-jp-morgan-healthcare-conference-302651456.html

SOURCE Haemonetics Corporation

FAQ

When will Haemonetics (HAE) present at the J.P. Morgan Healthcare Conference?

Haemonetics (HAE) will present on January 13, 2026 at 7:30 AM PT.

How can investors watch the Haemonetics (HAE) presentation at the J.P. Morgan Conference?

Investors can access the live audio webcast via the JPMorgan event link or through Haemonetics' Investor Relations Events & Presentations page.

Who from Haemonetics (HAE) will speak at the January 13, 2026 presentation?

Chris Simon, President and CEO of Haemonetics, will deliver the presentation.

Will there be a replay of the Haemonetics (HAE) presentation and for how long?

Yes. A replay will be available about one hour after the live event and will remain accessible for 30 days.

Where is the official webcast link to listen to Haemonetics (HAE) at the J.P. Morgan Conference?

The live audio webcast is available at the JPMorgan event URL and via Haemonetics' Investor Relations website under Events & Presentations.

Is the Haemonetics (HAE) J.P. Morgan presentation open to the public?

Yes. The presentation is available to the public via the audio webcast link and the company's investor website.